Is REPL or IVVD more profitable?

Replimune Group has a net margin of 0.00% compared to Invivyd's net margin of -138.90%. Invivyd's return on equity of -53.48% beat Replimune Group's return on equity. Company Net Margins Return on Equity Return on Assets Replimune Group N/A -128.57% -82.35% Invivyd -138.90% -53.48% -41.56%

Does the media prefer REPL or IVVD?

In the previous week, Replimune Group had 1 more articles in the media than Invivyd. MarketBeat recorded 3 mentions for Replimune Group and 2 mentions for Invivyd. Replimune Group's average media sentiment score of 0.95 beat Invivyd's score of 0.94 indicating that Replimune Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Replimune Group 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Invivyd 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, GLAS or IVVD?

Glass House Brands has higher revenue and earnings than Invivyd. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Glass House Brands $176.02M 4.54 N/A N/A N/A Invivyd $53.43M 3.37 -$52.49M -$0.31 N/A

Which has stronger earnings & valuation, IVA or IVVD?

Invivyd has higher revenue and earnings than Inventiva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inventiva $4.48M 206.64 -$400.67M N/A N/A Invivyd $53.43M 3.37 -$52.49M -$0.31 N/A

Is IVA or IVVD more profitable?

Inventiva has a net margin of 0.00% compared to Invivyd's net margin of -138.90%. Inventiva's return on equity of 0.00% beat Invivyd's return on equity. Company Net Margins Return on Equity Return on Assets Inventiva N/A N/A N/A Invivyd -138.90% -53.48% -41.56%

Does the media refer more to IVA or IVVD?

In the previous week, Inventiva had 1 more articles in the media than Invivyd. MarketBeat recorded 3 mentions for Inventiva and 2 mentions for Invivyd. Invivyd's average media sentiment score of 0.94 beat Inventiva's score of 0.53 indicating that Invivyd is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inventiva 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Invivyd 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer IVVD or TBPH?

In the previous week, Invivyd and Invivyd both had 2 articles in the media. Theravance Biopharma's average media sentiment score of 1.45 beat Invivyd's score of 0.94 indicating that Theravance Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Invivyd 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Theravance Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to AMPH or IVVD?

In the previous week, Amphastar Pharmaceuticals had 4 more articles in the media than Invivyd. MarketBeat recorded 6 mentions for Amphastar Pharmaceuticals and 2 mentions for Invivyd. Amphastar Pharmaceuticals' average media sentiment score of 1.08 beat Invivyd's score of 0.94 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amphastar Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Invivyd 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Invivyd (IVVD) Competitors

$0.61 +0.00 (+0.36%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$0.62 +0.01 (+0.92%)

As of 07/24/2026 07:34 PM Eastern

Compare

IVVD vs. REPL, GLAS, IVA, TBPH, and AMPH

Should you buy Invivyd stock or one of its competitors? MarketBeat compares Invivyd with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Invivyd include Replimune Group (REPL), Glass House Brands (GLAS), Inventiva (IVA), Theravance Biopharma (TBPH), and Amphastar Pharmaceuticals (AMPH). These companies are all part of the "pharmaceutical products" industry.

How does Invivyd compare to Replimune Group?

Replimune Group (NASDAQ:REPL) and Invivyd (NASDAQ:IVVD) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

In the previous week, Replimune Group had 1 more articles in the media than Invivyd. MarketBeat recorded 3 mentions for Replimune Group and 2 mentions for Invivyd. Replimune Group's average media sentiment score of 0.95 beat Invivyd's score of 0.94 indicating that Replimune Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Replimune Group	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Invivyd	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Replimune Group has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market. Comparatively, Invivyd has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market.

Replimune Group has a net margin of 0.00% compared to Invivyd's net margin of -138.90%. Invivyd's return on equity of -53.48% beat Replimune Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Replimune Group	N/A	-128.57%	-82.35%
Invivyd	-138.90%	-53.48%	-41.56%

92.5% of Replimune Group shares are held by institutional investors. Comparatively, 70.4% of Invivyd shares are held by institutional investors. 5.2% of Replimune Group shares are held by company insiders. Comparatively, 12.3% of Invivyd shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Replimune Group currently has a consensus target price of $8.86, suggesting a potential downside of 8.69%. Invivyd has a consensus target price of $8.00, suggesting a potential upside of 1,208.47%. Given Invivyd's stronger consensus rating and higher possible upside, analysts plainly believe Invivyd is more favorable than Replimune Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Replimune Group	2 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Invivyd	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Invivyd has higher revenue and earnings than Replimune Group. Replimune Group is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Replimune Group	N/A	N/A	-$313.94M	-$3.38	N/A
Invivyd	$53.43M	3.37	-$52.49M	-$0.31	N/A

Summary

Invivyd beats Replimune Group on 10 of the 15 factors compared between the two stocks.

How does Invivyd compare to Glass House Brands?

Glass House Brands (NYSE:GLAS) and Invivyd (NASDAQ:IVVD) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, media sentiment, institutional ownership, earnings and profitability.

Glass House Brands has higher revenue and earnings than Invivyd.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glass House Brands	$176.02M	4.54	N/A	N/A	N/A
Invivyd	$53.43M	3.37	-$52.49M	-$0.31	N/A

In the previous week, Invivyd had 1 more articles in the media than Glass House Brands. MarketBeat recorded 2 mentions for Invivyd and 1 mentions for Glass House Brands. Invivyd's average media sentiment score of 0.94 beat Glass House Brands' score of -1.00 indicating that Invivyd is being referred to more favorably in the news media.

Company	Overall Sentiment
Glass House Brands	Negative
Invivyd	Positive

Glass House Brands currently has a consensus target price of $17.00, suggesting a potential upside of 70.60%. Invivyd has a consensus target price of $8.00, suggesting a potential upside of 1,208.47%. Given Invivyd's higher possible upside, analysts plainly believe Invivyd is more favorable than Glass House Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glass House Brands	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Invivyd	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

70.4% of Invivyd shares are held by institutional investors. 12.3% of Invivyd shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Glass House Brands has a net margin of 0.00% compared to Invivyd's net margin of -138.90%. Glass House Brands' return on equity of 0.00% beat Invivyd's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glass House Brands	N/A	N/A	N/A
Invivyd	-138.90%	-53.48%	-41.56%

Summary

Glass House Brands beats Invivyd on 7 of the 13 factors compared between the two stocks.

How does Invivyd compare to Inventiva?

Inventiva (NASDAQ:IVA) and Invivyd (NASDAQ:IVVD) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, media sentiment, profitability and risk.

Inventiva has a beta of 0.72, meaning that its stock price is 28% less volatile than the broader market. Comparatively, Invivyd has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market.

Inventiva has a net margin of 0.00% compared to Invivyd's net margin of -138.90%. Inventiva's return on equity of 0.00% beat Invivyd's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inventiva	N/A	N/A	N/A
Invivyd	-138.90%	-53.48%	-41.56%

Inventiva currently has a consensus target price of $16.56, indicating a potential upside of 271.20%. Invivyd has a consensus target price of $8.00, indicating a potential upside of 1,208.47%. Given Invivyd's higher possible upside, analysts plainly believe Invivyd is more favorable than Inventiva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inventiva	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.09
Invivyd	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Inventiva had 1 more articles in the media than Invivyd. MarketBeat recorded 3 mentions for Inventiva and 2 mentions for Invivyd. Invivyd's average media sentiment score of 0.94 beat Inventiva's score of 0.53 indicating that Invivyd is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inventiva	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Invivyd	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Invivyd has higher revenue and earnings than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inventiva	$4.48M	206.64	-$400.67M	N/A	N/A
Invivyd	$53.43M	3.37	-$52.49M	-$0.31	N/A

19.1% of Inventiva shares are owned by institutional investors. Comparatively, 70.4% of Invivyd shares are owned by institutional investors. 32.0% of Inventiva shares are owned by insiders. Comparatively, 12.3% of Invivyd shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Inventiva beats Invivyd on 10 of the 15 factors compared between the two stocks.

How does Invivyd compare to Theravance Biopharma?

Invivyd (NASDAQ:IVVD) and Theravance Biopharma (NASDAQ:TBPH) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

Invivyd has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market. Comparatively, Theravance Biopharma has a beta of 0.17, meaning that its share price is 83% less volatile than the broader market.

Theravance Biopharma has higher revenue and earnings than Invivyd. Invivyd is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invivyd	$53.43M	3.37	-$52.49M	-$0.31	N/A
Theravance Biopharma	$107.46M	8.09	$105.89M	$2.20	7.66

70.4% of Invivyd shares are owned by institutional investors. Comparatively, 99.1% of Theravance Biopharma shares are owned by institutional investors. 12.3% of Invivyd shares are owned by insiders. Comparatively, 7.7% of Theravance Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Invivyd and Invivyd both had 2 articles in the media. Theravance Biopharma's average media sentiment score of 1.45 beat Invivyd's score of 0.94 indicating that Theravance Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Invivyd	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Theravance Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Theravance Biopharma has a net margin of 104.34% compared to Invivyd's net margin of -138.90%. Theravance Biopharma's return on equity of 18.84% beat Invivyd's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Invivyd	-138.90%	-53.48%	-41.56%
Theravance Biopharma	104.34%	18.84%	10.94%

Invivyd presently has a consensus price target of $8.00, suggesting a potential upside of 1,208.47%. Theravance Biopharma has a consensus price target of $19.40, suggesting a potential upside of 15.07%. Given Invivyd's stronger consensus rating and higher possible upside, equities research analysts plainly believe Invivyd is more favorable than Theravance Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invivyd	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Theravance Biopharma	0 Sell rating(s)	8 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Theravance Biopharma beats Invivyd on 10 of the 15 factors compared between the two stocks.

How does Invivyd compare to Amphastar Pharmaceuticals?

Amphastar Pharmaceuticals (NASDAQ:AMPH) and Invivyd (NASDAQ:IVVD) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and media sentiment.

In the previous week, Amphastar Pharmaceuticals had 4 more articles in the media than Invivyd. MarketBeat recorded 6 mentions for Amphastar Pharmaceuticals and 2 mentions for Invivyd. Amphastar Pharmaceuticals' average media sentiment score of 1.08 beat Invivyd's score of 0.94 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amphastar Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Invivyd	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Amphastar Pharmaceuticals has a net margin of 11.00% compared to Invivyd's net margin of -138.90%. Amphastar Pharmaceuticals' return on equity of 15.12% beat Invivyd's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amphastar Pharmaceuticals	11.00%	15.12%	7.14%
Invivyd	-138.90%	-53.48%	-41.56%

Amphastar Pharmaceuticals currently has a consensus target price of $22.00, suggesting a potential upside of 17.52%. Invivyd has a consensus target price of $8.00, suggesting a potential upside of 1,208.47%. Given Invivyd's stronger consensus rating and higher possible upside, analysts plainly believe Invivyd is more favorable than Amphastar Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amphastar Pharmaceuticals	2 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
Invivyd	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Amphastar Pharmaceuticals has a beta of 0.89, suggesting that its share price is 11% less volatile than the broader market. Comparatively, Invivyd has a beta of 0.67, suggesting that its share price is 33% less volatile than the broader market.

65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. Comparatively, 70.4% of Invivyd shares are owned by institutional investors. 29.6% of Amphastar Pharmaceuticals shares are owned by insiders. Comparatively, 12.3% of Invivyd shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Amphastar Pharmaceuticals has higher revenue and earnings than Invivyd. Invivyd is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amphastar Pharmaceuticals	$719.89M	1.15	$98.09M	$1.66	11.28
Invivyd	$53.43M	3.37	-$52.49M	-$0.31	N/A

Summary

Amphastar Pharmaceuticals beats Invivyd on 11 of the 16 factors compared between the two stocks.

Get Invivyd News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IVVD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IVVD vs. The Competition

Export

Metric	Invivyd	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$179.48M	$3.67B	$6.88B	$12.25B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-1.97	21.11	27.00	23.71
Price / Sales	3.37	164.10	492.66	73.79
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	0.59	7.88	10.28	6.07
Net Income	-$52.49M	$23.81M	$3.60B	$331.84M
7 Day Performance	-17.66%	-3.79%	-1.25%	-1.53%
1 Month Performance	-30.43%	-2.59%	-0.35%	-2.46%
1 Year Performance	-22.11%	32.85%	18.41%	13.66%

Invivyd Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IVVD Invivyd	2.6561 of 5 stars	$0.61 +0.4%	$8.00 +1,208.5%	-24.5%	$179.48M	$53.43M	N/A	100	Gap Up
REPL Replimune Group	1.2905 of 5 stars	$9.94 -9.6%	$8.13 -18.3%	+212.9%	$922.56M	N/A	N/A	210
GLAS Glass House Brands	N/A	$11.45 -3.0%	$17.00 +48.5%	N/A	$919.20M	$176.02M	N/A	N/A	Negative News Short Interest Increase
IVA Inventiva	2.3468 of 5 stars	$4.30 flat	$16.56 +285.0%	+35.8%	$893.14M	$5.07M	N/A	100
TBPH Theravance Biopharma	2.943 of 5 stars	$16.90 -0.2%	$19.40 +14.8%	+51.5%	$872.79M	$107.46M	7.68	110	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IVVD) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Invivyd (IVVD) Competitors

IVVD vs. REPL, GLAS, IVA, TBPH, and AMPH

How does Invivyd compare to Replimune Group?

Summary

How does Invivyd compare to Glass House Brands?

Summary

How does Invivyd compare to Inventiva?

Summary

How does Invivyd compare to Theravance Biopharma?

Summary

How does Invivyd compare to Amphastar Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IVVD vs. The Competition

Invivyd Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Invivyd (IVVD) Competitors

IVVD vs. REPL, GLAS, IVA, TBPH, and AMPH

How does Invivyd compare to Replimune Group?

Does the media prefer REPL or IVVD?

Which has more volatility and risk, REPL or IVVD?

Is REPL or IVVD more profitable?

Do institutionals & insiders believe in REPL or IVVD?

Do analysts rate REPL or IVVD?

Which has stronger earnings and valuation, REPL or IVVD?

Summary

How does Invivyd compare to Glass House Brands?

Which has higher valuation and earnings, GLAS or IVVD?

Does the media refer more to GLAS or IVVD?

Do analysts prefer GLAS or IVVD?

Do insiders & institutionals hold more shares of GLAS or IVVD?

Is GLAS or IVVD more profitable?

Summary

How does Invivyd compare to Inventiva?

Which has more volatility & risk, IVA or IVVD?

Is IVA or IVVD more profitable?

Do analysts prefer IVA or IVVD?

Does the media refer more to IVA or IVVD?

Which has stronger earnings & valuation, IVA or IVVD?

Do insiders & institutionals believe in IVA or IVVD?

Summary

How does Invivyd compare to Theravance Biopharma?

Which has more risk & volatility, IVVD or TBPH?

Which has better earnings & valuation, IVVD or TBPH?

Do insiders and institutionals hold more shares of IVVD or TBPH?

Does the media prefer IVVD or TBPH?

Is IVVD or TBPH more profitable?

Do analysts recommend IVVD or TBPH?

Summary

How does Invivyd compare to Amphastar Pharmaceuticals?

Does the media refer more to AMPH or IVVD?

Is AMPH or IVVD more profitable?

Do analysts prefer AMPH or IVVD?

Which has more risk & volatility, AMPH or IVVD?

Do institutionals and insiders hold more shares of AMPH or IVVD?

Which has preferable valuation & earnings, AMPH or IVVD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IVVD vs. The Competition

Invivyd Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools